Innoviva Inc
NASDAQ:INVA

Watchlist Manager
Innoviva Inc Logo
Innoviva Inc
NASDAQ:INVA
Watchlist
Price: 19.15 USD Market Closed
Market Cap: 1.2B USD
Have any thoughts about
Innoviva Inc?
Write Note

Innoviva Inc
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Innoviva Inc
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Innoviva Inc
NASDAQ:INVA
Cash from Operating Activities
$162.7m
CAGR 3-Years
-23%
CAGR 5-Years
-8%
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Cash from Operating Activities
$25.1B
CAGR 3-Years
-1%
CAGR 5-Years
2%
CAGR 10-Years
3%
Bristol-Myers Squibb Co
NYSE:BMY
Cash from Operating Activities
$15B
CAGR 3-Years
-1%
CAGR 5-Years
12%
CAGR 10-Years
14%
Pfizer Inc
NYSE:PFE
Cash from Operating Activities
$8B
CAGR 3-Years
-37%
CAGR 5-Years
-10%
CAGR 10-Years
-7%
Merck & Co Inc
NYSE:MRK
Cash from Operating Activities
$18.3B
CAGR 3-Years
12%
CAGR 5-Years
8%
CAGR 10-Years
4%
Eli Lilly and Co
NYSE:LLY
Cash from Operating Activities
$6B
CAGR 3-Years
-4%
CAGR 5-Years
7%
CAGR 10-Years
2%
No Stocks Found

Innoviva Inc
Glance View

Market Cap
1.2B USD
Industry
Pharmaceuticals

Innoviva, Inc. is engaged in the development, commercialization, and financial management of biopharmaceuticals. The company is headquartered in Burlingame, California and currently employs 5 full-time employees. The company went IPO on 2004-10-05. The firm's royalty portfolio contains respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/ vilanterol, FF/VI), ANORO ELLIPTA (umeclidinium bromide/ vilanterol, UMEC/VI) and TRELEGY ELLIPTA (the combination FF/UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, the Company is entitled to receive royalties from GSK on sales of RELVAR/BREO ELLIPTA and royalties from the sales of ANORO ELLIPTA. RELVAR/BREO ELLIPTA is a once-daily combination medicine consisting of a LABA, vilanterol (VI), and an inhaled corticosteroid (ICS), fluticasone furoate (FF). ANORO ELLIPTA is a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with an LABA, VI. TRELEGY ELLIPTA (the combination FF/UMEC/VI), a once-daily combination medicine consisting of an ICS, LAMA, and LABA.

INVA Intrinsic Value
18.73 USD
Overvaluation 2%
Intrinsic Value
Price

See Also

What is Innoviva Inc's Cash from Operating Activities?
Cash from Operating Activities
162.7m USD

Based on the financial report for Sep 30, 2024, Innoviva Inc's Cash from Operating Activities amounts to 162.7m USD.

What is Innoviva Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-8%

Over the last year, the Cash from Operating Activities growth was 39%. The average annual Cash from Operating Activities growth rates for Innoviva Inc have been -23% over the past three years , -8% over the past five years .

Back to Top